Skip to content

Abstract 17924: Bivalirudin versus Heparin in Patients Undergoing Veno-Arterial Extracorporeal Membrane Oxygenation: A Multicenter Propensity-Matched Analysis

Nov 2026 · Circulation · 0 citations

Abstract

Background: Patients undergoing veno-arterial extracorporeal membrane oxygenation (VA-ECMO) require systemic anticoagulation but remain at high risk for bleeding and thrombotic complications. Unfractionated heparin is commonly used, while bivalirudin has emerged as an alternative; however, comparative real-world outcome data remain limited. We evaluated short-term outcomes associated with bivalirudin versus heparin among adults undergoing VA-ECMO. Methods: We performed a retrospective cohort study using the TriNetX US Collaborative Network. Adults aged ≥18 years who underwent VA-ECMO between January 1, 2015 and April 30, 2025 and received bivalirudin or heparin within 3 days of ECMO initiation were identified. Patients were compared after 1:1 propensity score matching for demographics, comorbidities, markers of illness severity, vasopressor use, antiplatelet therapy, and baseline laboratory parameters. Outcomes were assessed from day 3 through day 14 after ECMO initiation. Time-to-event outcomes were assessed using Kaplan-Meier analysis and hazard ratios were estimated using Cox proportional hazards regression. Outcomes included all-cause mortality, bleeding composite (hemoptysis, melena, hematemesis, other gastrointestinal bleeding or intracranial hemorrhage), blood product transfusion, ECMO-related/postprocedural hemorrhage, and thrombotic composite (cerebral infarction, intracardiac thrombosis, pulmonary embolism, or acute extremity embolism). Results: Before matching, 1,178 patients received bivalirudin and 5,278 received heparin. After propensity score matching, 1,158 patients were included in each group. All-cause mortality did not differ significantly between bivalirudin and heparin groups (22.6% vs 24.1%; HR 0.92, 95% CI 0.78-1.09; p=0.339). The bleeding composite was also similar between groups (HR 1.05, 95% CI 0.86-1.29; p=0.603). Bivalirudin was associated with a lower hazard of transfusion (20.5% vs 26.1%; HR 0.76, 95% CI 0.64-0.90; p=0.001), but a higher hazard of ECMO-related/postprocedural hemorrhage (4.6% vs 2.7%; HR 1.71, 95% CI 1.10-2.66; p=0.017). There were no significant differences in thrombotic events (HR 1.11, 95% CI 0.91-1.35; p=0.306). Conclusion: In this large multicenter propensity-matched cohort of adults undergoing VA-ECMO, bivalirudin and heparin were associated with similar short-term mortality, bleeding composite, and thrombotic events. Bivalirudin was associated with lower transfusion hazard but higher ECMO-related/postprocedural hemorrhage, highlighting a nuanced safety profile that warrants further prospective evaluation.

View source

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.